Definitive Contract 75A50123C00010

This federal contract award to the Albert B. Sabin Vaccine Institute, Inc. (Sabin Vaccine Institute) is for the manufacture of Sabin's Sudan Ebolavirus vaccine, including the bulk drug substance (BDS) and final drug product (FDP). The contract has a total ceiling value of $209,156,148.00 and is a definitive, cost-plus-fixed-fee contract with a period of performance ending on September 30, 2030. The contract was awarded on December 29, 2022 by the Office of the Assistant Secretary for Preparedness and Response (ASPR), which is a civilian agency within the U.S. Department of Health and Human Services (HHS). This contract award appears to be tied to a previous Broad Agency Announcement (BAA) issued by BARDA, the Biomedical Advanced Research and Development Authority, which is focused on the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats.